Patent DE197955C successfully refreshed from Google Patents.
Patent US4265873A successfully refreshed from Google Patents.
US4265873A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for typing human leukocyte antigens
Assignee: Wisconsin Alumni Research Foundation
•
Filing: 1978-07-03
•
Granted: 1981-05-05
•
Expires: 1998-07-03
Abstract
Abstract A cellular method for typing lymphocyte defined human leukocyte antigens by utilizing human blood leukocytes which have been sensitized to proliferatively respond to the secondary stimulus of the leukocyte antigens to which they have been sensitized. The sensitization is accomplished by incubating, in vitro, in a mixed leukocyte culture, the leukocytes to be sensitized with leukocytes differing by only a single major histocompatibility complex haplotype or a single HLA-D antigenic determinant.
Inventors
- 👤 Michael J. Sheehy
- 👤 Paul M. Sondel
- 👤 Fritz H. Bach
- 👤 Marilyn L. Bach
- 👤 Rudolf Wank
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 12:45
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/0005; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/543; G01N33/554
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
125 words
A method for typing human leukocyte antigens of HLA-D which comprises: incubating, in vitro, purified human blood leukocytes obtained from two individuals, where the leukocytes from one of the individuals have been treated to prevent their proliferation during incubation; carrying out the incubation for a period of from about 9 to about 14 days to essential completion of the proliferative response; recovering the leukocytes from the incubation medium; incubating, in vitro, the thus recovered leukocytes, with purified human blood leukocytes obtained from a third individual; measuring the response of the recovered leukocytes through the uptake by the responding leukocytes of tritiated thymidine or tritiated uridine added to the incubating mixture; and utilizing said measurement as a definition of the antigens present in the third individual.
Claim 2
Independent Claim
125 words
A method for typing human leukocyte antigens of HLA-D which comprises: incubating, in vitro, purified human blood leukocytes obtained from two individuals, where the leukocytes from one of the individuals have been treated to prevent their proliferation during incubation; carrying out the incubation for a period of from about 9 to about 14 days to essential completion of the proliferative response; recovering the leukocytes from the incubation medium; incubating, in vitro, the thus recovered leukocytes, with purified human blood leukocytes obtained from a third individual; measuring the response of the recovered leukocytes through the uptake by the responding leukocytes of tritiated thymidine or tritiated uridine added to the incubating mixture; and utilizing said measurement as a definition of the antigens present in the third individual.
Claim 3
Dependent Claim
30 words
The method of claim 1 wherein the leukocytes of one of the first two individuals differs from those of the other individual by only a single major histocompatibility complex haplotype.
Claim 4
Dependent Claim
24 words
The method of claim 1 wherein the treatment of the leukocytes to prevent proliferation during incubation comprises exposure of the leukocytes to gamma radiation.
Claim 5
Dependent Claim
23 words
The method of claim 1 wherein the treatment of the leukocytes to prevent proliferation during incubation comprises contacting the leukocytes with mitomycin C.
Claim 6
Dependent Claim
22 words
The method of claim 1 wherein the leukocytes obtained from the third individual have been treated to prevent their proliferation during incubation.
Claim 7
Dependent Claim
14 words
The method of claim 1 wherein the initial incubation is terminated at 10 days.
Claim 8
Dependent Claim
55 words
A reagent for lymphocyte defined typing of human leukocyte antigens which comprises human blood leukocytes which have been sensitized to proliferatively respond to the secondary stimulus of the leukocyte antigens to which they have been sensitized, said sensitization being accomplished by incubating, in vitro, the leukocytes to be sensitized with leukocytes of different LD haplotypes.
Claim 9
Dependent Claim
55 words
A reagent for lymphocyte defined typing of human leukocyte antigens which comprises human blood leukocytes which have been sensitized to proliferatively respond to the secondary stimulus of the leukocyte antigens to which they have been sensitized, said sensitization being accomplished by incubating, in vitro, the leukocytes to be sensitized with leukocytes of different LD haplotypes.
Claim 10
Dependent Claim
32 words
The reagent according to claim 7 in which the sensitization is accomplished by incubating, in vitro, the leukocytes to be sensitized with leukocytes differing by only a single major histocompatibility complex haplotype.
References Cited (Backward Citations)
US3900461A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-05-04 | 1984-11-03 | 1985-05-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-05-04 | 1988-11-03 | 1989-05-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-05-04 | 1992-11-03 | 1993-05-05 | $7700.00 | Window Closed / Lapsed |